Literature DB >> 15172967

Pathobiology of hemophilic synovitis I: overexpression of mdm2 oncogene.

Narine Hakobyan1, Tamara Kazarian, Adnan A Jabbar, Kausar J Jabbar, Leonard A Valentino.   

Abstract

Hemophilia is a genetic disease caused by a deficiency of blood coagulation factor VIII or IX. Bleeding into joints is the most frequent manifestation of hemophilia. Hemarthrosis results in an inflammatory and proliferative disorder termed hemophilic synovitis (HS). In time, a debilitating, crippling arthritis, hemophilic arthropathy, develops. Although the clinical sequence of events from joint bleeding to synovitis to arthropathy is well documented, the component or components in blood and the molecular changes responsible for hemophilic synovitis are not known. Iron has long been suspected to be the culprit but direct evidence has been lacking. Previously, we showed that iron increased human synovial cell proliferation and induced c-myc expression. Here we show that bleeding into a joint in vivo and iron in vitro result in increased expression of the p53-binding protein, mdm2. Iron induced the expression of mdm2 by normal human synovial cells approximately 8-fold. In a murine model of human hemophilia A, hemarthrosis resulted in pathologic changes observed in human hemophilic synovitis and a marked increase in synovial cell proliferation. Iron, in vitro, induced the expression of mdm2. The molecular changes induced by iron in the blood may be the basis of the increase in cell proliferation and the development of hemophilic synovitis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15172967     DOI: 10.1182/blood-2003-12-4231

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  24 in total

1.  TAFI deficiency causes maladaptive vascular remodeling after hemophilic joint bleeding.

Authors:  Tine Wyseure; Tingyi Yang; Jenny Y Zhou; Esther J Cooke; Bettina Wanko; Merissa Olmer; Ruchi Agashe; Yosuke Morodomi; Niels Behrendt; Martin Lotz; John Morser; Annette von Drygalski; Laurent O Mosnier
Journal:  JCI Insight       Date:  2019-10-03

2.  Neoangiogenesis contributes to the development of hemophilic synovitis.

Authors:  Suchitra S Acharya; Rosandra N Kaplan; Dan Macdonald; Oluwa T Fabiyi; Donna DiMichele; David Lyden
Journal:  Blood       Date:  2010-12-16       Impact factor: 22.113

3.  Assessing joint involvement in haemophilia by clinical rheumatologic scores. A pilot study on similarities with subjects with psoriatic arthritis.

Authors:  Matteo Nicola Dario Di Minno; Salvatore Iervolino; Rosario Peluso; Antonio del Puente; Anna Russolillo; Antonio Coppola; Carlo Ruosi; Anna Guida; Raffaele Scarpa; Giovanni Di Minno
Journal:  Clin Rheumatol       Date:  2011-02-16       Impact factor: 2.980

4.  EPCR deficiency or function-blocking antibody protects against joint bleeding-induced pathology in hemophilia mice.

Authors:  Jhansi Magisetty; Usha R Pendurthi; Charles T Esmon; L Vijaya Mohan Rao
Journal:  Blood       Date:  2020-06-18       Impact factor: 22.113

5.  Vascular remodeling underlies rebleeding in hemophilic arthropathy.

Authors:  Vikas Bhat; Merissa Olmer; Shweta Joshi; Donald L Durden; Thomas J Cramer; Richard Fw Barnes; Scott T Ball; Tudor H Hughes; Mauricio Silva; James V Luck; Randy E Moore; Laurent O Mosnier; Annette von Drygalski
Journal:  Am J Hematol       Date:  2015-10-08       Impact factor: 10.047

Review 6.  Orthopedic disorders of the knee in hemophilia: A current concept review.

Authors:  E Carlos Rodriguez-Merchan; Leonard A Valentino
Journal:  World J Orthop       Date:  2016-06-18

Review 7.  Advances and challenges in hemophilic arthropathy.

Authors:  Tine Wyseure; Laurent O Mosnier; Annette von Drygalski
Journal:  Semin Hematol       Date:  2015-10-26       Impact factor: 3.851

8.  Components in Plasma-Derived Factor VIII, But Not in Recombinant Factor VIII Downregulate Anti-Inflammatory Surface Marker CD163 in Human Macrophages through Release of CXCL4 (Platelet Factor 4).

Authors:  Anne Bertling; Martin F Brodde; Mayken Visser; Janina Treffon; Michelle Fennen; Anke C Fender; Reinhard Kelsch; Beate E Kehrel
Journal:  Transfus Med Hemother       Date:  2017-08-11       Impact factor: 3.747

9.  Beyond stopping the bleed: short-term episodic prophylaxis with recombinant activated factor FVII in haemophilia patients with inhibitors.

Authors:  Silva Zupančić Šalek; Günter Auerswald; Gary Benson; Gerry Dolan; Anne Duffy; Cedric Hermans; Victor Jiménez-Yuste; Rolf Ljung; Massimo Morfini; Elena Santagostino; Thierry Lambert
Journal:  Blood Transfus       Date:  2015-12-01       Impact factor: 3.443

Review 10.  Haemophilia.

Authors:  Erik Berntorp; Kathelijn Fischer; Daniel P Hart; Maria Elisa Mancuso; David Stephensen; Amy D Shapiro; Victor Blanchette
Journal:  Nat Rev Dis Primers       Date:  2021-06-24       Impact factor: 52.329

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.